Research Notes Open Access

Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics

Callie M. Blase1, Brandon K. Rouault1, Maia B. Zoller1, Joshua V. Luff1, Emma J. Lerch1, Brynn N. Lauterbachq1, Mark A. Brown1, Joachim Storsberg2 and Christian Schmidt2
  • 1 Colorado State University, United States
  • 2 Fraunhofer-Institute for Applied Polymer Research , Germany
American Journal of Immunology
Volume 15 No. 1, 2019, 19-21

DOI: https://doi.org/10.3844/ajisp.2019.19.21

Submitted On: 14 August 2019
Published On: 13 September 2019

How to Cite: Blase, C. M., Rouault, B. K., Zoller, M. B., Luff, J. V., Lerch, E. J., Lauterbachq, B. N., Brown, M. A., Storsberg, J. & Schmidt, C. (2019). Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics. American Journal of Immunology, 15(1), 19-21. https://doi.org/10.3844/ajisp.2019.19.21

Abstract

The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.

Download

Keywords

  • Commercial Exclusivity
  • FDA
  • Immunologic Agents
  • Antibody-based Therapeutics